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citrate and magnesium (P < 0.01) compared with the intact 
animals. Treatment with prophylactic regimen of crocin (20 
and 40 mg/kg) significantly reduced the elevated oxalate, 
and increased the citrate and magnesium levels of urine. 
The attenuation of protein loss was only seen with a high 
dose of crocin in a prophylactic study. Urine volume was 
not significantly altered after EG or crocin administration. 
The increased number of calcium deposits in the kidney tis-
sue of lithiatic rats was decreased after prophylactic treat-
ment with 20 and 40 mg/kg of crocin. The urinary ionic 
parameters and crystal count were not significantly altered 
after the therapeutic study. A marked increase in malon-
dialdehyde (MDA, a lipid peroxidation product) level was 
observed in the EG-given group. Treatment with crocin (20 
and 40 mg/kg) reduced the elevated levels of MDA. Results 
indicate that crocin can be effective in preventing urine cal-
culi formation and recurrence of the disease. The mecha-
nism underlying this effect is mediated possibly through 
balancing promoter and inhibitor factors and an antioxidant 
effect.
Keywords crocin · Saffron · Kidney stone · 
Hyperoxaluria · Nephrolithiasis · Calcium oxalate · 
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Introduction
Urinary tract stones (urolithiasis) are the third prevalent 
disorder affecting the urinary system. This disorder arises 
as a result of a cascade of events initiated by supersatura-
tion, crystal nucleation, growth, aggregation, retention and 
migration to the renal papillary surfaces [1, 2]. Almost 
80 % of all kidney stones are predominately composed of 
CaOx [3]. High recurrence rate of this disorder is worrying 
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and long-term treatment strategies have been inadequate [4, 
5].
For years, medicinal plants have become an important 
source of new chemical substances with potential therapeu-
tic effects.
Saffron, the dried stigmas of Crocus sativus L., (fam-
ily, Iridaceae), is native to the Mediterranean environment 
and widely cultivated in Iran [6]. Traditionally, this plant 
has been used as a colorant and seasoning in food. Moreo-
ver, in folklore medicine, saffron has been used in numer-
ous illnesses including cough, asthma, menstruation prob-
lems, insomnia, pain, colic, chronic uterine hemorrhage, 
painful urination, kidney stone, cardiovascular disorders 
and tumors [7–9]. Avicenna, a Persian physician and the 
most famous philosopher–scientist of the Islamic world, 
described the details of a remedy, consisting of saffron plus 
honey, prescribed to facilitate the passage of kidney stones 
[10]. Saffron extracts and its active constituents, safranal 
and crocin, have shown anti-cancer [11, 12], antioxidant 
[13], hypolipidemic and insulin resistance improvement 
[14], protection against cisplatin-induced acute renal fail-
ure [15], and anti-convulsant [16], anti-depressant [17, 18], 
anti-anxiety [19], anti-nociceptive and anti-inflammatory 
properties [20–22]. In this study we investigated the pos-
sible effect of crocin, a main water-soluble carotenoid of 
C. sativus as a preventive or curative agent against ethylene 
glycol-induced lithiasis using male Wistar rats.
Materials and methods
Materials
Hydrochlorothiazide was donated by Darupaksh Pharma-
ceutical Co., Tehran, Iran. Potassium citrate was purchased 
from Sepidaj Pharmaceutical Co., Tehran, Iran. Ethylene 
glycol (EG) was provided by Merck (Germany). Malondi-
aldehyde was obtained from Fluca (Switzerland). Thiobar-
bituric acid (TBA) was purchased from Merck (Germany). 
crocin was extracted in our laboratory and purified [23]. 
The purity of crocin crystals was tested with HPLC and 
was more than 90 % [23]. The applied doses of crocin were 
based on previous studies [19, 24]. crocin and standard 
drugs were dissolved in normal saline and given once daily 
by the intraperitoneal (i.p.) route.
Animals
Male Wistar rats with the weight range of 190–200 g were 
obtained from the animal house of the school of Phar-
macy, Mashhad University of Medical Sciences, Mash-
had, Iran. They were maintained under a 12 h light–dark 
cycle environment. Animals had access to food and water 
ad libitum throughout the study. All the procedures were 
approved by Mashhad University of Medical Sciences and 
followed the internationally accepted Principles for Labo-
ratory Animal Use and Care [25].
Experimental design
Ethylene glycol-induced hyperoxaluria model [3] was used 
to induce nephrolithiasis. Animals were randomly divided 
into ten groups of six rats each. Rats serving as intact con-
trol group received tap drinking water for 30 days.
Untreated control group received intraperitoneal (i.p.) 
injection of normal saline (2.5 ml/kg) along with renal lith-
ogenic treatment containing 1 % v/v ethylene glycol (EG) 
for 30 days.
Positive control group received co-treatment of potas-
sium citrate (2.5 g/kg) and 1 % v/v EG from the 1st day 
to 30th day of calculi induction [26]. Hydrochlorothiazide 
(HCTZ, 10 mg/kg, i.p.), as a diuretic drug, plus EG (1 % 
v/v) for 30 days was chosen for measuring diuretic activ-
ity. Prophylactic groups of study received crocin, 10, 20 
and 40 mg/kg respectively, concomitant with 1 % v/v EG 
from the 1st day to 30th day of calculi induction. Curative 
groups of study received 1 % v/v EG from the 1st day to 
30th day of study with crocin at doses of 10, 20 and 40 mg/
kg administered from the 14th day to 30th day of calculi 
induction.
Collection and analysis of urine
For assessment of diuretic activity, the volume of total urine 
excreted out during the first 24 h after lithogenic treatment 
or day 1 was determined [27].
All animals were kept separately in metabolic cages and 
24 h urine samples were collected on 0, 1 and 30th day of 
calculi induction treatment. Following volume determina-
tion of urine, samples were stored at −20 °C and those 
collected on days 0 and 30 were analyzed for PH, oxalate, 
phosphate, uric acid, citrate, magnesium and total pro-
tein (Darman Cov, Ltd, Iran) according to manufacturer’s 
protocol.
Collection and analysis of tissue for histological assays
After the last urine collection, the kidneys were isolated 
from killed animals and washed in ice‐cold saline. The 
right kidneys were fixed in 10 % neutral buffered forma-
lin. The 5 μm-thick sections were stained via a hematoxy-
lin and eosin solution and examined by light microscopy. 
Calcium oxalate deposits of slides were randomly counted 
using an Olympus microscope, type BX 40, with a magni-
fication of 40×. As described previously, a sagittal section 
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of each kidney sample was divided into eight equal-sized 
parts by four virtual lines, to count the number of crystal-
line deposits, as shown in Fig. 1 [28]. The total number of 
CaOx deposits in each sample was reported as average of 
the eight readings. The histological slides were examined 
by a pathologist who was blind to the experiment.
Collection and analysis of tissue for determination of lipid 
peroxidation
Antioxidant potential of crocin was estimated by its inhibi-
tory effect against lipid peroxidation induced in the kidney 
homogenate by measuring MDA concentration, accord-
ing to Uchiyama et al. [29] procedure. Following decapi-
tation, the left kidney was rapidly removed, washed in 
ice‐cold saline and immersed in liquid nitrogen. Frozen 
samples were homogenized (10 % w/v) in 2 ml of 1.15 % 
w/v potassium chloride solution. 3 ml of phosphoric acid 
(1 % w/v) and 1 ml of TBA (0.6 % w/v) were added to 
0.5 ml of homogenate in a centrifuge tube. After stirring, 
all samples and standards (a set of MDA standards over 
the concentration range of 0–50 nmol/ml) were heated at 
100 °C for 45 min. After cooling, 4 ml of n-butanol was 
added to the mixture and vortex mixed for 1 min, followed 
by centrifugation at 3,000 rpm for 15 min. The butanol 
layer was transferred to a fresh tube and its absorbance 
was read at 525 nm. The levels of MDA were expressed as 
nmol/mg of tissue.
Statistical analysis
The results were expressed as mean ± standard error mean 
(SEM). The statistical significance was assessed using two-
way analysis of variance (ANOVA) followed by Bonfer-
roni’s comparison test or by paired t test. P values less than 
0.05 were considered as significant. The crystal deposit 
number was analyzed by one-way ANOVA followed by 
Tukey’s pairwise comparison. The Statistical Package for 
the Social Science (SPSS® for Windows, release 13) was 
used for statistical analysis.
Results
Effect on the urine output
Determination of the first 24 h (day 1) urine output revealed 
that the diuretic drug, HCTZ (10 mg/kg), increased the 
urine volume as compared to lithiatic and intact con-
trol groups (P < 0.01). As shown in Table 1, crocin at the 
administered doses in this study did not show a diuretic 
effect after 24 h of stone induction compared to lithiatic 
control.
Although the urinary volume of lithiatic animals 
increased on day 30 after the stone-inducing treatment by 
EG, it was not significant compared to day 0 and the intact 
control group. The urinary output at this time on treatment 
with crocin also showed no statistically significant change 
compared to the lithiatic control group (Table 1).
Effect on the urinary parameters
No difference in biochemical parameters was found among 
the groups on day 0. As a result of stone induction with EG, 
there was an increased oxalate excretion in lithiatic rats 
on the 30th day as compared to day 0 and normal control 
group (P < 0.05, P < 0.01 respectively). However, the pro-
phylactic regimen of crocin (20 and 40 mg/kg) for 1 month 
significantly prevented the elevated levels of urinary oxa-
late excretion (Table 2). Low dose of crocin (10 mg/kg) 
failed to exhibit significant reduction in urinary oxalate 
excretion. In a curative study, crocin did not significantly 
decrease urinary oxalate, compared to the stone-inducing 
group (Table 2). After 30 days of stone induction, urinary 
pH in nephrolithiasic animals treated with normal saline 
showed no significant change in comparison to the intact 
control group. There was also no appreciable change to the 
urinary PH of animals treated with crocin to that of lithiatic 
or intact control groups (Table 2).
At the 30th day on stone-inducing regimen, the excre-
tion of phosphate increased in the EG-treated rats, but not 
to a significant extent. Following treatment with either pro-
phylactic or curative regimens of crocin, urinary phosphate 
was not significantly altered, as indicated in Table 2.
The urine concentration of citrate was decreased by 
stone-inducing treatment as compared to day 0 and normal 
control group (P < 0.05, P < 0.01, respectively), whereas 
only 40 mg/kg of crocin in the prophylactic regimen sig-
nificantly (P < 0.01) improved the reduction of renal citrate 
content (Table 3). Renal stone induction caused significant 
decrease (P < 0.01) in the magnesium levels of urine in 
Fig. 1  Four virtual lines divide each kidney sagittal section into eight 
equal parts
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group II (Table 3), which was dose-dependently prevented 
in the animals receiving a simultaneous treatment with 
crocin as a prophylactic regimen. In the curative regimen 
too, a similar pattern was observed on increasing the mag-
nesium contents of urine.
Renal stone induction caused urinary protein loss 
compared to day 0 and normal control group (P < 0.05, 
P < 0.001 respectively), which was dose-dependently pre-
vented in animals receiving a simultaneous treatment with 
the applied doses of crocin in the prophylactic regimen 
(Table 4).
The uric acid level in urine was not changed to any sig-
nificant extent after EG-induced renal stone in the lithiatic 
control group or crocin-treated groups (data not shown).
Effect on lipid peroxidation
Lithogenic treatment enhanced the MDA (P < 0.05) content 
in the kidney of rats that received normal saline compared 
to the control animals. A co-administration with crocin 
(20 and 40 mg/kg) protected against the lipid peroxidation 
induced by stone-inducing treatment (P < 0.05) (Fig. 2).
Histopathologic findings
On histopathological examination, EG-induced lithiatic 
rats showed a marked increase in the deposition of calcium 
oxalate crystals along with interstitial infiltration, as com-
pared to normal control (P < 0.001, Table 4; Fig. 3). How-
ever, a simultaneous treatment with 20 and 40 mg/kg crocin 
as prophylactic regimen significantly reduced the ele-
vated levels of calcium oxalate crystals in the renal tissue 
(P < 0.001, P < 0.05; respectively, Table 4; Fig. 2). Potas-
sium citrate-fed rats as a positive control group showed a 
marked decrease in the number of stones as compared to 
lithiatic animals that received normal saline (P < 0.001).
The kidney deposits of CaOx crystals were not sig-
nificantly lower than the respective lithiatic group in ani-
mals treated with a curative regimen of crocin (figures not 
shown).
Discussion
The annual incidence and prevalence of urinary tract 
stones is increasing, while the age of onset of this disor-
der is decreasing, probably due to change in dietary life-
style, habits, diets, hypertension and obesity [30, 31]. 
Despite recent advances in the treatment of kidney stones 
with modern techniques such as extracorporeal shock wave 
lithotripsy, high cost, several adverse effects and the recur-
rence of stones limit their usefulness. The low efficacy of 
current drugs such as alkali citrate and thiazide diuretics, in Ta
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addition to their lesser tolerability, necessitates the consid-
erable need for finding new drugs [1, 32, 33]. Herbal medi-
cines have shown protective effects in different in vitro 
and in vivo models of urolithiasis, perhaps due to multiple 
constituents acting through different pathways [34–38]. In 
the present study, the prophylactic and curative effects of 
crocin, a main pharmacologically active component of C. 
sativus, were evaluated against ethylene glycol-induced 
nephrolithiasis in rats. Only male rats were used in this 
study because the prominence of stone induction is more in 
male rats compared to female ones. There is a close simi-
larity between the urinary system of these animals and that 
of humans [3]. It has been reported that female sex hor-
mones can inhibit renal crystal deposition in EG-treated 
rats through suppressing urinary oxalate excretion and the 
expression of osteopontin (OPN) [39]. It has been indicated 
that chronic administration of EG, which is oxidized to 
oxalic acid by nonspecific dehydrogenase, causes increased 
renal retention and excretion of oxalate and the formation 
of renal calculi composed mainly of calcium oxalate [37, 
38]. Consistent with previous reports, in the present study, 
oxalate increased in animals treated with EG for 30 days. 
It has been demonstrated that hyperoxaluria is a major risk 
factor in the pathogenesis of renal calculi [40]. The elevated 
levels of oxalate provide an environment appropriate for 
calculi induction through forming calcium oxalate crystals. 
Although decreased levels of urinary PH has been reported 
in some studies [41], in the present study the PH of urine 
did not significantly change over a period of 30 days of EG 
administration, which is in accordance with the results of Ta
bl
e 
4 
 
Ef
fe
ct
 o
f c
ro
ci
n 
on
 C
aO
x 
cr
ys
ta
l d
ep
os
iti
on
 n
um
be
r i
n 
ur
ol
ith
ia
sis
-in
du
ce
d 
ra
ts
Va
lu
es
 a
re
 ex
pr
es
se
d 
as
 m
ea
n 
± 
SE
M
. A
ll 
co
m
po
un
ds
 w
er
e 
ad
m
in
ist
er
ed
 b
y 
th
e 
in
tra
pe
rit
on
ea
l r
ou
te
*
 
P 
<
 
0.
05
, *
**
 
P 
<
 
0.
00
1 
vs
 li
th
ia
tic
 g
ro
up
 (I
I),
 by
 on
e-w
ay
 A
N
OV
A
 fo
llo
w
ed
 b
y 
Tu
ke
y’
s 
po
st 
ho
c 
te
st
G
ro
up
 (n
 
= 
6)
In
ta
ct
 c
on
tro
l
Li
th
ia
tic
 o
r  
n
eg
at
iv
e 
co
n
tr
ol
Po
sit
iv
e 
co
n
tr
ol
  
(K
 ci
tra
te,
  
2.
5 
g/
kg
)
Pr
op
hy
la
ct
ic
al
ly
 
tr
ea
te
d 
w
ith
  
cr
o
ci
n 
(10
 
m
g/
kg
)
Pr
op
hy
la
ct
ic
al
ly
 
tr
ea
te
d 
w
ith
  
cr
o
ci
n 
(20
 
m
g/
kg
)
Pr
op
hy
la
ct
ic
al
ly
 
tr
ea
te
d 
w
ith
  
cr
o
ci
n 
(40
 
m
g/
kg
)
Cu
ra
tiv
el
y 
tre
at
ed
 
w
ith
 c
ro
ci
n 
 
(10
 
m
g/
kg
)
Cu
ra
tiv
el
y 
tre
at
ed
 
w
ith
 c
ro
ci
n 
 
(20
 
m
g/
kg
)
Cu
ra
tiv
el
y 
tre
at
ed
 
w
ith
 c
ro
ci
n 
(40
 
m
g/
kg
)
Ca
O
x 
cr
ys
ta
l d
ep
os
i-
tio
n 
nu
m
be
r
4.
3 
± 
2.
9*
**
72
7 
± 
11
8
9.
8 
± 
4.
8*
**
47
3 
± 
12
1
30
6.
8 
± 
10
7.
4*
12
1.
6 
± 
63
**
*
58
7 
± 
99
44
4 
± 
62
38
7 
± 
96
Fig. 2  Effect of crocin (10, 20, 40 mg/kg, i.p.) on the MDA con-
tent in the kidney tissues of male Wistar rats. Data are shown as 
mean ± SEM (n = 4). Significance was determined by one-way 
ANOVA followed by Tukey’s post hoc test: *P < 0.05, vs. EG-treated 
group. #P < 0.05, vs. intact control group
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Green et al. [42], who concluded that metabolic acidosis 
does not develop in conventional EG treatments, but may 
result from renal insufficiency induced by oxalate load.
A decreased level of urinary citrate and magnesium 
was observed in the ethylene glycol-induced urolithic 
rats. The low levels of citrate and magnesium are impor-
tant risk factors for stone formation in the kidney [1]. 
These protective factors prevent crystallization of salts in 
urine. Citrate complexes with calcium ions and reduces 
urinary supersaturation of calcium salts. As a result, crystal 
growth and aggregation are inhibited. Furthermore, citrate 
increases the activity of some macromolecules in urine, 
such as Tamm–Horsfall protein that inhibits calcium oxa-
late aggregation and may reduce the expression of urinary 
osteopontin (OPN), an important component of the protein 
matrix of urinary stones. Magnesium can also form com-
plexes with oxalate and decrease supersaturation. In addi-
tion, the excretion of citrate in urine has been reported to 
Fig. 3  Light microscopic architecture and calcium oxalate deposits 
in the kidney sections in the preventive study. Arrows indicate the 
crystals in the cortex, tubule and medulla (×40) of rat at 30 days. 
Kidney sections of (a) intact control, b lithiatic (negative control), 
c potassium citrate-treated (positive control) rat, and d rats treated 
with crocin at a dose of 40 mg/kg, e 20 mg/kg and f 10 mg/kg (h and 
e 400)
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be elevated after administration of magnesium [1, 43–45]. 
The urinary citrate excretion reached normal levels follow-
ing prophylactic treatment with 40 mg/kg of crocin and 
potassium citrate as a positive control. Magnesium levels 
of urine were restored on the supplementation with prophy-
lactic and curative regimens of crocin in a dose-dependent 
manner. No significantly increased excretion of uric acid 
and phosphate was observed in the lithiatic group when 
compared with intact control animals, which is in agree-
ment with the Shirfule et al. study [46]. It might be specu-
lated that increased levels of such factors need more con-
centration of EG or longer exposure to it.
The present observation showed that protein excretion 
increased in the lithogenic treatment with ethylene glycol, 
which is as a result of proximal tubular dysfunction [47, 
48]. Urinary protein loss was brought down significantly by 
the prophylactic regimen of crocin (20 and 40 mg/kg), but 
not at a low dose of 10 mg/kg of crocin.
There was limited or no crystal formation in animals 
receiving 20 and 40 mg/kg of prophylactic treatment of 
crocin.
It has been indicated that hyperoxaluria induces per-
oxidative damage to the renal tubular membrane surface 
(lipid peroxidation), which in turn leads to the production 
of superoxide and hydroxyl free radicals, oxidative stress-
induced cell membrane rupture, cell death (apoptosis) and 
subsequent development of calcium oxalate urinary stone 
generation [49, 50]. The involvement of oxidative stress 
has also been demonstrated in the kidneys of stone-form-
ing patients [51]. Therefore, a reduction of renal oxidative 
stress could be an effective therapeutic approach [52]. Anti-
oxidants such as vitamin E, catechin and selenium have 
been reported to prevent hyperoxaluria-induced calcium 
oxalate crystal deposition [49, 53]. It was observed that 
oxidative damage as reflected from the increased level of 
MDA, a marker of oxidative injury, significantly increased 
in the kidneys of the stone-forming group; however, pro-
phylactic crocin at the dose of 20 and 40 mg/kg attenuated 
the content of MDA in the kidneys of lithogenic rats. Sup-
plementation with potassium citrate also improved urinary 
citrate and magnesium and reduced oxalate and crystals 
number; however, it did not reduce the urinary lipid peroxi-
dation product, MDA.
It is suggested that the nephroprotective effects of crocin 
in the EG-induced urolithiasis model could be through 
maintaining balance between stone promoters and inhibi-
tors, reducing deposition of CaOX crystals from the kidney 
and preventing the EG-induced lipid peroxidation.
Antioxidant and anti-inflammatory properties of this 
promising agent have been shown in various studies [19, 
54, 55]. For example, an aqueous extract of saffron and 
crocin prevented renal ischemia–reperfusion induced 
oxidative injury through antioxidant effect in rats [56]. 
Following cisplatin-induced acute renal failure in mice, 
crocin elicited a protective effect by suppressing rela-
tive oxidative stress [15]. Thushara et al. [57] showed that 
platelet aggregation induced by oxidative stress was inhib-
ited by crocin through an anti-apoptotic pathway. In a study 
conducted by Jnaneshwari et al. [58], cyclophosphamide-
induced organ toxicity was prevented by crocin through 
modulating antioxidant status and inflammatory cytokines. 
Crocin prevented apoptosis following retinal ischemia/rep-
erfusion damage through the PI3K/AKT signaling pathway 
[59]. In a study by Xu et al. [60], crocin inhibited xylene-
induced ear edema in mice and carrageenan-induced paw 
edema as well as production of lipopolysaccharide-induced 
prostaglandin E2 (PGE2) in rats. Crocin and crocetin 
reduced LPS-induced nitric oxide (NO) release, TNF-α, 
IL-1β, intracellular ROS and NF-κB activation from cul-
tured rat brain microglial cells [61]. Crocin showed anti-
oxidant activity in the liver and kidney of streptozotocin-
induced diabetic rats [62]. Recently, crocin has been 
reported to protect against beryllium chloride toxicity in 
rats through antioxidant effect and enhancing gene expres-
sion of antioxidant enzymes in a study by El-Beshbishy 
HA and co-workers [63].
Considering that infection is probably associated with 
the urolithiasis process, antimicrobial activity may also 
contribute to the antilithiatic effect of crocin [64].
The safety profile of crocin in animals or humans 
has been reported in some studies. In a study conducted 
by Wang et al. on rats, a very low toxicity of crocin was 
reported. A daily dose of crocin (50 mg/kg for 8 days) did 
not affect hepatic function; however, a higher dosage of 
100 mg/kg for 2 weeks caused hepatic damage and black 
pigmentation, but a lower dose of 100 mg/kg for 40 days 
did not. Rats receiving 1 % of crocin dyes for 4 months 
elicited mild hepatic functional disorders and pigmentation, 
which was completely reversible [65].
A recent study, evaluating biochemical, hematologi-
cal and pathological criteria in mice and rats treated with 
crocin (up to 3 g, p.o. and i.p. as well as 15–180 mg/kg, 
i.p.), showed no damage to any major organs in the body. 
In a randomized, double-blind, controlled trial on volun-
teers treated with crocin tablets (20 mg) for a duration of 1 
month, no major adverse events were observed during the 
trial [66].
As, at the doses tested in the present study, crocin 
showed its effect in the early stages of stone development 
and did not reverse the established crystal deposits in the 
curative study, it is helpful to prevent the recurrence of the 
disease, one of the biggest challenges in urolithic patients. 
Hence, consumption of this agent in the prophylactic regi-
mens might be a good strategy.
One of the limitations in this study is that Ca2+, a facili-
tating factor for nucleation and precipitation of calcium 
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oxalate, was not evaluated in our study. However, consid-
ering that urinary oxalate execration is a more important 
factor in the induction of CaOx deposition [42, 52], the 
elevated levels of this factor could be a reason to guarantee 
the formation of CaOx calculi.
In addition, intraperitoneal administration of crocin was 
used in this study. Considering that oral administration of 
drugs is the preferred route of drug delivery [67], further 
studies are necessary to examine the effect of oral adminis-
tration of the effective doses of crocin in this study on the 
biochemical parameters in urine and blood.
It should be noted that orally administered crocin is not 
absorbed either after a single dose or repeated dose, due to 
hydrolysis of crocin to crocetin in the intestinal tract [68]. 
Hence, crocetin might be a better compound for further 
studies in this topic.
Conclusion
Taken together, it has been suggested that crocin, the main 
carotenoid constituent of C. sativus with a wide spectrum of 
therapeutic potentials, could be useful as either alternative or 
an adjunctive therapy in the management of kidney stones. 
Antioxidant activity seems to be an important factor in medi-
ating the antilithiatic effects of this compound. However, fur-
ther studies are required to determine the exact mechanisms 
by which crocin prevents EG-induced nephrolithiasis.
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